CHICAGO — A multidisciplinary group of menopause experts developed new comorbidity-specific guidance on non-hormone therapy for moderate-to-severe vasomotor symptoms.
First-Line Recommendations
For patients whose primary menopausal symptoms are hot flashes and night sweats, first-line neurokinin (NK)-receptor antagonists are recommended. Alternative or second-line treatment options include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, and oxybutynin, noted JoAnn Pinkerton, MD, of the University of Virginia Health System in Charlottesville, at ENDO 2026, the annual meeting of the Endocrine Society.
Evidence for NK-Receptor Antagonists
NK-receptor antagonists, like fezolinetant (Veozah) and elinzanetant (Lynkuet), have strong evidence for managing hot flashes, Pinkerton said, and while access is limited, it is improving.
Products to Avoid
The group opted not to recommend clonidine due to rebound hypertension, as well as most herbal and over-the-counter products, since better options are available.
Common Symptoms and Treatment Challenges
Pinkerton stressed that hot flashes are common and disruptive to menopausal women, and hormone therapy is contraindicated for or declined by many patients.
Fuente: https://www.medpagetoday.com/meetingcoverage/endo/121789
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
